دورية أكاديمية
أعرض في EDS

Persistent tailoring of MSC activation through genetic priming.

التفاصيل البيبلوغرافية
العنوان: Persistent tailoring of MSC activation through genetic priming.
المؤلفون: Beauregard MA; Department of Bioengineering, Rice University, Houston, TX, USA., Bedford GC; Department of Bioengineering, Rice University, Houston, TX, USA., Brenner DA; Department of Bioengineering, Rice University, Houston, TX, USA., Sanchez Solis LD; Department of Bioengineering, Rice University, Houston, TX, USA., Nishiguchi T; The Global Tuberculosis Program, Texas Children's Hospital, Immigrant and Global Health, WTS Center for Human Immunobiology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA., Abhimanyu; The Global Tuberculosis Program, Texas Children's Hospital, Immigrant and Global Health, WTS Center for Human Immunobiology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA., Longlax SC; The Global Tuberculosis Program, Texas Children's Hospital, Immigrant and Global Health, WTS Center for Human Immunobiology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA., Mahata B; Department of Bioengineering, Rice University, Houston, TX, USA., Veiseh O; Department of Bioengineering, Rice University, Houston, TX, USA., Wenzel PL; Department of Integrative Biology & Pharmacology, The University of Texas Health Science Center at Houston, Houston, TX, USA.; Center for Stem Cell and Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.; Immunology Program, The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA., DiNardo AR; The Global Tuberculosis Program, Texas Children's Hospital, Immigrant and Global Health, WTS Center for Human Immunobiology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands., Hilton IB; Department of Bioengineering, Rice University, Houston, TX, USA., Diehl MR; Department of Bioengineering, Rice University, Houston, TX, USA.; Department of Chemistry, Rice University, Houston, TX, USA.
المصدر: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2024 Aug 08; Vol. 32 (3), pp. 101316. Date of Electronic Publication: 2024 Aug 08 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101624857 Publication Model: eCollection Cited Medium: Print ISSN: 2329-0501 (Print) Linking ISSN: 23290501 NLM ISO Abbreviation: Mol Ther Methods Clin Dev Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2017- : Cambridge, MA : Cell Press
Original Publication: New York, NY : Nature Publishing Group, [2014]-
مستخلص: Mesenchymal stem/stromal cells (MSCs) are an attractive platform for cell therapy due to their safety profile and unique ability to secrete broad arrays of immunomodulatory and regenerative molecules. Yet, MSCs are well known to require preconditioning or priming to boost their therapeutic efficacy. Current priming methods offer limited control over MSC activation, yield transient effects, and often induce the expression of pro-inflammatory effectors that can potentiate immunogenicity. Here, we describe a genetic priming method that can both selectively and sustainably boost MSC potency via the controlled expression of the inflammatory-stimulus-responsive transcription factor interferon response factor 1 (IRF1). MSCs engineered to hyper-express IRF1 recapitulate many core responses that are accessed by biochemical priming using the proinflammatory cytokine interferon-γ (IFN-γ). This includes the upregulation of anti-inflammatory effector molecules and the potentiation of MSC capacities to suppress T cell activation. However, we show that IRF1-mediated genetic priming is much more persistent than biochemical priming and can circumvent IFN-γ-dependent expression of immunogenic MHC class II molecules. Together, the ability to sustainably activate and selectively tailor MSC priming responses creates the possibility of programming MSC activation more comprehensively for therapeutic applications.
Competing Interests: The authors have submitted a pending provisional patent application related to this work.
(© 2024 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.)
التعليقات: Update of: bioRxiv. 2024 Feb 07:2024.02.01.578489. doi: 10.1101/2024.02.01.578489. (PMID: 38370626)
References: Nat Commun. 2023 Feb 10;14(1):735. (PMID: 36759517)
Cell Rep. 2018 Feb 27;22(9):2504-2517. (PMID: 29490284)
Cell Mol Immunol. 2023 Jun;20(6):558-569. (PMID: 36973490)
Front Neurosci. 2014 Feb 06;8:12. (PMID: 24567701)
Blood. 2006 Mar 15;107(6):2570-7. (PMID: 16293599)
Nat Commun. 2022 Sep 29;13(1):5730. (PMID: 36175404)
Front Bioeng Biotechnol. 2022 Apr 01;10:859927. (PMID: 35433656)
Cell Death Dis. 2020 May 11;11(5):349. (PMID: 32393744)
Immune Netw. 2015 Oct;15(5):241-51. (PMID: 26557808)
Cell Rep. 2022 Jun 7;39(10):110914. (PMID: 35675777)
Stem Cell Res Ther. 2022 Mar 24;13(1):124. (PMID: 35321737)
Sci Rep. 2021 Apr 9;11(1):7825. (PMID: 33837229)
Trends Pharmacol Sci. 2020 Sep;41(9):653-664. (PMID: 32709406)
Cancer Res. 2014 Mar 1;74(5):1576-87. (PMID: 24452999)
Front Cell Dev Biol. 2022 Feb 17;10:700702. (PMID: 35252164)
J Allergy Clin Immunol. 2017 May;139(5):1667-1676. (PMID: 27670240)
Front Cell Dev Biol. 2021 Jul 23;9:654210. (PMID: 34368115)
Immunol Cell Biol. 2018 Nov;96(10):1095-1103. (PMID: 29893425)
Front Immunol. 2022 Jul 18;13:917790. (PMID: 35924240)
J Biomed Sci. 2021 Apr 14;28(1):28. (PMID: 33849537)
Nat Rev Immunol. 2005 Oct;5(10):793-806. (PMID: 16200082)
Blood Adv. 2020 May 12;4(9):1987-1997. (PMID: 32384543)
Sci Rep. 2014 Apr 10;4:4645. (PMID: 24717973)
EBioMedicine. 2018 Feb;28:261-273. (PMID: 29366627)
Stem Cells Int. 2019 Mar 10;2019:3675627. (PMID: 30956667)
Acta Pharm Sin B. 2023 Jun;13(6):2778-2794. (PMID: 37425054)
Int J Mol Sci. 2022 Aug 10;23(16):. (PMID: 36012170)
Stem Cell Res Ther. 2022 Jul 28;13(1):367. (PMID: 35902956)
Front Immunol. 2018 May 28;9:1135. (PMID: 29892288)
Stem Cell Res Ther. 2019 May 2;10(1):131. (PMID: 31046833)
Cell. 2023 Feb 2;186(3):621-645.e33. (PMID: 36736301)
Cell Death Dis. 2018 Mar 7;9(3):386. (PMID: 29515165)
World J Stem Cells. 2023 Aug 26;15(8):787-806. (PMID: 37700823)
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2598-E2607. (PMID: 28283659)
Cell Death Differ. 2014 Feb;21(2):216-25. (PMID: 24185619)
Cell. 2020 Sep 3;182(5):1252-1270.e34. (PMID: 32818467)
Biomater Sci. 2020 Sep 15;8(18):5061-5070. (PMID: 32797143)
Int J Mol Med. 2015 May;35(5):1309-16. (PMID: 25777747)
Stem Cell Res Ther. 2023 Apr 7;14(1):66. (PMID: 37024925)
Stem Cells Transl Med. 2017 Jan;6(1):223-237. (PMID: 28170190)
Front Cell Dev Biol. 2021 Feb 16;9:632717. (PMID: 33665190)
Sci Adv. 2020 Jul 22;6(30):eaba6884. (PMID: 32832666)
Eur J Immunol. 2008 Aug;38(8):2325-36. (PMID: 18601229)
Int J Mol Sci. 2022 Apr 14;23(8):. (PMID: 35457151)
NPJ Regen Med. 2019 Dec 2;4:22. (PMID: 31815001)
Nat Rev Immunol. 2014 Jan;14(1):36-49. (PMID: 24362405)
Nat Commun. 2022 Aug 31;13(1):5118. (PMID: 36045140)
Mol Ther Methods Clin Dev. 2020 Jan 22;16:204-224. (PMID: 32071924)
Stem Cells. 2017 May;35(5):1259-1272. (PMID: 28181347)
Transplantation. 2003 Feb 15;75(3):389-97. (PMID: 12589164)
Stem Cell Res Ther. 2021 Jan 7;12(1):37. (PMID: 33413597)
Nat Rev Immunol. 2018 Sep;18(9):545-558. (PMID: 29921905)
Immunol Cell Biol. 2018 May;96(5):536-548. (PMID: 29446493)
Cell Death Discov. 2015 Aug 24;1:15007. (PMID: 27551443)
Cytotherapy. 2016 Sep;18(9):1114-28. (PMID: 27421739)
Stem Cell Res Ther. 2020 Sep 25;11(1):416. (PMID: 32988406)
Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1269-81. (PMID: 27033518)
Signal Transduct Target Ther. 2022 Mar 21;7(1):92. (PMID: 35314676)
Cancers (Basel). 2023 May 24;15(11):. (PMID: 37296860)
معلومات مُعتمدة: R01 DK111599 United States DK NIDDK NIH HHS
فهرسة مساهمة: Keywords: IRF1; STAT1; immunomodulation; immunosuppression; interferon gamma licensing; mesenchymal stem cells; priming; signaling pathway engineering
تواريخ الأحداث: Date Created: 20240916 Latest Revision: 20240924
رمز التحديث: 20240924
مُعرف محوري في PubMed: PMC11396059
DOI: 10.1016/j.omtm.2024.101316
PMID: 39282077
قاعدة البيانات: MEDLINE
الوصف
تدمد:2329-0501
DOI:10.1016/j.omtm.2024.101316